NCT07102030 Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
| NCT ID | NCT07102030 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Stockholm |
| Condition | Systemic Lupus Erythematosus |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2015-02-15 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2015-02-15 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to investigate different phenotypes among patients with SLE and to compare with matched general population controls. The main questions we aim to answer are: A To investigate if subgroups of patients with systemic lupus erythematosus (SLE) defined by autoantibodies, genetic predisposition or biomarkers, rather than the present diagnostic entities account for the high risk of premature vascular disease. B To perform in depth studies of selected patient groups to shed light on the autoimmune mechanisms behind antiphospholipid (aPL) antibodies and nephritis and their association to vascular disease in SLE and APS Participants will be investigated in person by a nurse and a rheumatologist. Data on previous and present disease characteristics, anthropometric measurements and health related quality of life (according to selfreported questionnaires) will be entered into a data base. Blood samples (plasma serum and DNA), urine and saliva is stored in a corresponding biobank. Researchers will compare identified subgroups of SLE patients to each other and to matched population controls.
Eligibility Criteria
Inclusion Criteria: SLE according to criteria (ACR82 or SLICC 2012) and consenting to participate Exclusion Criteria: Not possible to read and understand patient information due to language barriers or psychological/psychiatric disorders Not consenting \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07102030 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Systemic Lupus Erythematosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07102030 currently recruiting?
Yes, NCT07102030 is actively recruiting participants. Contact the research team at elisabet.svenungsson@ki.se for enrollment information.
Where is the NCT07102030 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT07102030 clinical trial?
NCT07102030 is sponsored by Region Stockholm. The trial plans to enroll 900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.